Association of cystatin C with adverse outcomes

Purpose of reviewTo discuss recent studies which have evaluated determinants of cystatin C and to focus on the relationship of cystatin C with mortality, cardiovascular disease (CVD), and noncardiovascular outcomes. Recent findingsIn the Chronic Kidney Disease Epidemiology Study cystatin C was associated with demographic characteristics independent of measured glomerular filtration rate (GFR), although this was to a smaller extent than creatinine. In patients with established chronic kidney disease (CKD), cystatin C was strongly and inversely correlated with measured GFR, suggesting that although cystatin C may have other determinants, it is primarily a measure of kidney function. Several cohort studies, particularly in older adults, have now demonstrated that cystatin C is linearly associated with mortality, CVD and non-CVD outcomes, whereas creatinine is primarily associated with risk in individuals with more advanced kidney disease. A recent study has also shown that changes in kidney function as ascertained by cystatin C, even within the relatively normal range, are associated with subsequent CVD and all-cause mortality among older adults. SummaryCystatin C appears to capture an association of mild kidney disease with increased risk of mortality, CVD and non-CVD outcomes. Future studies should evaluate whether cystatin C can improve medical decision-making and lead to favorable patient outcomes.

[1]  D. Siscovick,et al.  Rapid kidney function decline and mortality risk in older adults. , 2008, Archives of internal medicine.

[2]  D. Levy,et al.  Association of visceral and subcutaneous adiposity with kidney function. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[3]  B. Hyman,et al.  Serum cystatin C and the risk of Alzheimer disease in elderly men , 2008, Neurology.

[4]  L. Hansson,et al.  Cystatin C--a marker of peripheral atherosclerotic disease? , 2008, Atherosclerosis.

[5]  C. Rosano,et al.  Cystatin C as a marker of cognitive function in elders: Findings from the health ABC study , 2008, Annals of neurology.

[6]  Anders Larsson,et al.  Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. , 2008, The New England journal of medicine.

[7]  B. Kestenbaum,et al.  Differences in Kidney Function and Incident Hypertension: The Multi-Ethnic Study of Atherosclerosis , 2008, Annals of Internal Medicine.

[8]  Devin Mann,et al.  Overweight, obesity, and elevated serum cystatin C levels in adults in the United States. , 2008, The American journal of medicine.

[9]  M. Shlipak Cystatin C: research priorities targeted to clinical decision making. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  C. Schmid,et al.  Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  A. Köttgen,et al.  Serum cystatin C in the United States: the Third National Health and Nutrition Examination Survey (NHANES III). , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  B. Psaty,et al.  Cystatin C concentration as a predictor of systolic and diastolic heart failure. , 2008, Journal of cardiac failure.

[13]  B. Kestenbaum,et al.  Cystatin C and aging success. , 2008, Archives of internal medicine.

[14]  T. Kurth,et al.  Cystatin C and risk of heart failure in the Physicians' Health Study (PHS). , 2008, American heart journal.

[15]  M. Staufenbiel,et al.  Cystatin C modulates cerebral β-amyloidosis , 2007, Nature Genetics.

[16]  R. Hui,et al.  Cystatin C, Associated With Hemorrhagic and Ischemic Stroke, Is a Strong Predictor of the Risk of Cardiovascular Events and Death in Chinese , 2007, Stroke.

[17]  G. Beck,et al.  Cystatin C as a Risk Factor for Outcomes in Chronic Kidney Disease , 2007, Annals of Internal Medicine.

[18]  M. Trevisan,et al.  Elevated Cystatin C Concentration and Progression to Pre-Diabetes , 2007, Diabetes Care.

[19]  B. Zinman,et al.  Cystatin C is associated with cardiovascular risk factors and metabolic syndrome in Aboriginal youth , 2007, Pediatric Nephrology.

[20]  D. McManus,et al.  Association of cystatin C with poor exercise capacity and heart rate recovery: data from the heart and soul study. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[21]  S. Cummings,et al.  Renal function and risk of hip and vertebral fractures in older women. , 2007, Archives of internal medicine.

[22]  M. Staufenbiel,et al.  Cystatin C modulates cerebral beta-amyloidosis. , 2007, Nature genetics.

[23]  B. Kestenbaum,et al.  Association of kidney function with incident hip fracture in older adults. , 2007, Journal of the American Society of Nephrology : JASN.

[24]  A. Newman,et al.  Cystatin C and measures of physical function in elderly adults: the Health, Aging, and Body Composition (HABC) Study. , 2006, American journal of epidemiology.

[25]  Karine Clément,et al.  Cathepsin s promotes human preadipocyte differentiation: possible involvement of fibronectin degradation. , 2006, Endocrinology.

[26]  B. Kestenbaum,et al.  Cystatin C and Prognosis for Cardiovascular and Kidney Outcomes in Elderly Persons without Chronic Kidney Disease , 2006, Annals of Internal Medicine.

[27]  J. Cauley,et al.  Kidney function predicts the rate of bone loss in older individuals: the Cardiovascular Health Study. , 2006, The journals of gerontology. Series A, Biological sciences and medical sciences.

[28]  Anne B. Newman,et al.  Chronic Kidney Disease and Functional Limitation in Older People: Health, Aging and Body Composition Study , 2006, Journal of the American Geriatrics Society.

[29]  S. Cummings,et al.  Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. , 2005, Journal of the American Society of Nephrology : JASN.

[30]  D. Siscovick,et al.  Cystatin C and incident peripheral arterial disease events in the elderly: results from the Cardiovascular Health Study. , 2005, Archives of internal medicine.

[31]  Anne Newman,et al.  Cystatin C and subclinical brain infarction. , 2005, Journal of the American Society of Nephrology : JASN.

[32]  P. Chaves,et al.  Kidney function as a predictor of noncardiovascular mortality. , 2005, Journal of the American Society of Nephrology : JASN.

[33]  D. Siscovick,et al.  Cystatin C and the risk of death and cardiovascular events among elderly persons. , 2005, The New England journal of medicine.

[34]  R. Nelson,et al.  Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. , 2005, Journal of the American Society of Nephrology : JASN.

[35]  L. Fried,et al.  Cystatin C Concentration as a Risk Factor for Heart Failure in Older Adults , 2005, Annals of Internal Medicine.

[36]  F. Bogazzi,et al.  Thyroid function differently affects serum cystatin Cand creatinine concentrations , 2005, Journal of endocrinological investigation.

[37]  H. Brenner,et al.  Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. , 2005, Clinical chemistry.

[38]  B. Psaty,et al.  Cystatin-C and mortality in elderly persons with heart failure. , 2005, Journal of the American College of Cardiology.

[39]  L. Hansson,et al.  Cystatin C: A Novel Predictor of Outcome in Suspected or Confirmed Non–ST-Elevation Acute Coronary Syndrome , 2004, Circulation.

[40]  D. Spiegelman,et al.  Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. , 2004, Kidney international.

[41]  V. Dharnidharka,et al.  Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[42]  L. Risch,et al.  Effects of glucocorticoid immunosuppression on serum cystatin C concentrations in renal transplant patients. , 2001, Clinical chemistry.

[43]  P. Ridker,et al.  Plasma levels of cystatin-C and mannose binding protein are not associated with risk of developing systemic atherosclerosis , 2001, Vascular medicine.

[44]  S H Ferris,et al.  Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. , 1997, JAMA.

[45]  N W Shock,et al.  Longitudinal Studies on the Rate of Decline in Renal Function with Age , 1985, Journal of the American Geriatrics Society.